TADILAS FILM-COATED TABLETS 5MG

Krka, d.d., Novo mesto (SLOVENIA)🇸🇬 Health Sciences Authority

Approval Date: Aug 24, 2022
Approval ID: bc40ca7793f9e685
Company: Krka, d.d., Novo mesto (SLOVENIA)
Type: Therapeutic

Approval Details

Approval Id: bc40ca7793f9e685
Drug Name: TADILAS FILM-COATED TABLETS 5MG
Product Name: TADILAS FILM-COATED TABLETS 5MG
Approval Number: SIN16581P
Approval Date: 2022-08-24
Registrant: SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Licence Holder: SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET, FILM COATED
Dosage: 4.2 Posology and method of administration Posology Erectile dysfunction Tadilas for Use as Needed The recommended dose is 10 mg taken prior to anticipated sexual activity. In those patients in whom tadalafil 10 mg does not produce an adequate effect, the maximum dose is 20 mg and the maximum dosing frequency is once per day. It may be taken from 30 minutes to 36 hours prior to sexual activity. Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use. Tadilas for Once Daily Use In patients who anticipate a frequent use of Tadilas (i.e. at least twice weekly) a once daily regimen with the lowest doses of Tadilas might be considered suitable, based on patient choice and the physician’s judgement. In these patients the recommended starting dose is 2.5 mg once a day, taken at approximately the same time every day, without regard to timing of sexual activity. The dose may be increased to 5 mg once a day, based on individual efficacy and tolerability. The appropriateness of continued use of the daily regimen should be reassessed periodically. Benign prostatic hyperplasia The recommended dose is 5 mg, taken at approximately the same time every day. When therapy for BPH is initiated with Tadilas and finasteride, the recommended dose of Tadilas is 5 mg, taken at approximately the same time every day for up to 26 weeks. Erectile Dysfunction and Benign Prostatic Hyperplasia The recommended dose is 5 mg, taken at approximately the same time every day, without regard to timing of sexual activity. Elderly men Dose adjustments are not required in elderly patients. Men with renal impairment Tadilas for Use as Needed <ul> <li>Mild (creatinine clearance 51 to 80 ml/min): No dose adjustment is required.</li> <li>Moderate (creatinine clearance 31 to 50 ml/min): A starting dose of 5 mg not more than once per day is recommended and the maximum dose is 10 mg not more than once in every 48 hours.</li> <li>Severe (creatinine clearance < 30 ml/min or on hemodialysis): The maximum dose is 5 mg not more than once in every 72 hours (see section 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> </ul> Tadilas for Once Daily Use <ul> <li>Mild (creatinine clearance 51 to 80 ml/min): No dose adjustment is required.</li> <li>Moderate (creatinine clearance 31 to 50 ml/min): No dose adjustment is required.</li> <li>Severe (creatinine clearance < 30 ml/min or on hemodialysis): Tadilas for once daily use is not recommended (see section 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> </ul> Men with hepatic impairment Tadilas for Use as Needed The recommended dose is 10 mg taken prior to anticipated sexual activity. There is limited clinical data on the safety of Tadilas in patients with severe hepatic impairment (Child-Pugh Class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment. Tadilas for Once Daily Use Once-a-day dosing has not been extensively evaluated in patients with hepatic impairment; therefore, if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician (see section 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Men with diabetes Dose adjustments are not required in diabetic patients. Paediatric population Tadilas should not be used in individuals below 18 years of age. Patients taking CYP3A4 Inhibitors Tadilas for Use as Needed For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of Tadilas is 10 mg, not to exceed once every 72 hours (see section 4.4 and 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) Tadilas for Once Daily Use For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of Tadilas is 2.5 mg (see section 4.4 and 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Method of administration For oral use. Tadilas can be taken with or without food.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Treatment of erectile dysfunction (ED) in adult males. In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required. Treatment of the signs and symptoms of benign prostatic hyperplasia (BHP). If Tadilas is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks. Treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED/BPH). Tadilas is not indicated for use by women.
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway. Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Tadalafil must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated: <ul class="dash"> <li>patients with myocardial infarction within the last 90 days,</li> <li>patients with unstable angina or angina occurring during sexual intercourse,</li> <li>patients with New York Heart Association Class 2 or greater heart failure in the last 6 months,</li> <li>patients with uncontrolled arrhythmias, hypotension (< 90/50 mm Hg), or uncontrolled hypertension,</li> <li>patients with a stroke within the last 6 months.</li> </ul> Tadalafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous phosphodiesterase type 5 (PDE5) inhibitor exposure (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Atc Code: G04BE08
Atc Item Name: tadalafil
Pharma Manufacturer Name: SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

Active Ingredients

Tadalafil

5.000mg

TADALAFIL

5 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Aug 24, 2022

Approval ID

bc40ca7793f9e685

Type

Therapeutic

Back to HSA Approvals